The ZNF737-CXCL10 axis drives immune exclusion and resistance to anti-PD-1 therapy in bladder cancer

ZNF737 is a pivotal, tumor cell-intrinsic repressor that establishes an immune-excluded and cytotoxicity-resistant TME in BLCA. Our findings establish ZNF737 as a mechanistic driver of immune evasion and a powerful PD-L1-complementary biomarker for predicting ICB resistance. These results position ZNF737 as a high-priority therapeutic target for developing "cold-to-hot" combination strategies in bladder cancer.

Authors

Institutions

Publication Details

Journal
International Immunopharmacology
Published
2026-03-04
DOI
https://doi.org/10.1016/j.intimp.2026.116443
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The ZNF737-CXCL10 axis drives immune exclusion and resistance to anti-PD-1 therapy in bladder cancer

Luzhe Yan, Dingshan Deng, Zhongyu Dai, Jiatong Xiao et al.
International Immunopharmacology
Bladder and Urothelial Cancer Treatments
article

The ZNF737-CXCL10 axis drives immune exclusion and resistance to anti-PD-1 therapy in bladder cancer

Luzhe Yan, Dingshan Deng, Zhongyu Dai, Jiatong Xiao, Haisu Liang, Xin Gao, Yifan Liu, Rongxin Liu, Jinhui Liu, Xuan Wen, Xiongbing Zu, Ruizhe Wang, Tao Guo, Wenqi Yang
article en

Abstract

ZNF737 is a pivotal, tumor cell-intrinsic repressor that establishes an immune-excluded and cytotoxicity-resistant TME in BLCA. Our findings establish ZNF737 as a mechanistic driver of immune evasion and a powerful PD-L1-complementary biomarker for predicting ICB resistance. These results position ZNF737 as a high-priority therapeutic target for developing "cold-to-hot" combination strategies in bladder cancer.

International ImmunopharmacologyVol. 175
Huaqiao University (CN), Central South University (CN), Xinjiang Medical University (CN), First Affiliated Hospital of Xinjiang Medical University (CN), Changsha Normal University (CN), First Affiliated Hospital of Guangzhou Medical University (CN), Fourth Hospital of Changsha (CN), Xiangya Hospital Central South University (CN), Guangzhou Medical University (CN)
Reduced inequalities
Openalex Percentile: Top 34%
Bladder and Urothelial Cancer Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

The ZNF737-CXCL10 axis drives immune exclusion and resistance to anti-PD-1 therapy in bladder cancer — Luzhe Yan, Dingshan Deng, et al. · International Immunopharmacology (2026) | TGRS Research Map | TGRS